Advait Gupta

5682 POSTS
Advait is our expert writer and manager for the Artificial Intelligence category. His passion for AI research and its advancements drives him to deliver in-depth articles that explore the frontiers of this rapidly evolving field. Advait's articles delve into the latest breakthroughs, trends, and ethical considerations, keeping readers at the forefront of AI knowledge.

Exclusive articles:

Tech giants spend less while Nvidia sells boatloads of GPUs

Tech giants struggle with austerity as Nvidia's GPU sales surge, raising questions about their spending restraint. Find out more here.

Nigeria’s MyCover.ai to expand its open insurance API platform with fresh funding

MyCover.ai secures $1.25 million in funding, aims to revolutionize insurance in Africa with open API and streamlined claims process.

James Cameron: AI-generated scripts are word salad and won’t replace human writers

James Cameron questions the capabilities of AI in scriptwriting, while researchers and industry professionals debate its potential. Strike action highlights the concern of writers and actors, but some see AI as a creative tool. The future of AI in the arts remains uncertain.

Biden administration to impose limits on China tech investment by 2024

The Biden administration plans to impose restrictions on Chinese tech investments, targeting cutting-edge sectors such as semiconductor and AI. These restrictions are expected to take effect in 2024, aiming to protect US interests while potentially hindering collaboration and innovation. Find out more about the impact it may have on the global tech arena.

Temasek China executive highlights lack of profitability route for AI firms in A-share market

Temasek's hesitance to invest in generative AI companies in A-share market due to lack of profitability routes & viable business models.

Breaking

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.

Pioneering Research Uncovers Vital Biomarker for Orbital Inflammation

An in-depth study reveals HLF as a potential biomarker for orbital inflammation, offering new insights for diagnosis and treatment strategies.
spot_imgspot_img